Research Topics
| Ann S LaCasceSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce
Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
Semin Hematol 45:85-9. 2008..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseAnn S LaCasce
Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
Blood 119:2093-9. 2012..98). RCHOP was inferior to RHCVAD and RCHOP+HDT/ASCR, which had similar PFS and OS. Despite aggressive regimens, the median PFS was 3 to 4 years. Future trials should focus on novel agents rather than comparing current approaches... 
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 26:5107-12. 2008..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...- Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplantAndrew A Lane
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Leuk Lymphoma 53:1130-6. 2012..0037). Increased vigilance for symptoms of pneumonitis is warranted for patients with prior mediastinal radiation and for younger patients, and dose reduction may be considered for patients who would receive greater than 1000 mg of BCNU... - Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Cancer 118:2944-51. 2012.... - High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national databaseGregory A Abel
Brigham and Women s Hospital, Boston, MA, USA
Leuk Lymphoma 53:1113-6. 2012..Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up... - Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioningPhilippe Armand
Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
J Clin Oncol 26:5767-74. 2008..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression... - Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography eraPhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Br J Haematol 160:608-17. 2013.... - Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapyAmy M Fox
Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
Int J Radiat Oncol Biol Phys 83:277-83. 2012..This study sought to quantify the risk of radiation pneumonitis (RP) in Hodgkin lymphoma (HL) patients receiving mediastinal radiation therapy (RT) and to identify predictive factors for RP... - Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients Yi Bin Chen
Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
Leuk Lymphoma 51:789-96. 2010..In conclusion, patients who fail R-CHOP appear to benefit from ASCT, but they may have a worse prognosis compared to patients who fail CHOP alone... - Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphomaGregory M Cote
MGH Cancer Center, Boston, Massachusetts 02114 2617, USA
Biol Blood Marrow Transplant 18:76-83. 2012..Although these outcomes are encouraging, longer follow-up is required and comparison with other traditional ASCT regimens used for patients with non-Hodgkin lymphoma (NHL) is warranted... - Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemiaPhilip C Amrein
Massachusetts General Hospital Cancer Center, Medical Oncology and Department of Biostatistics, Dana Farber Cancer Institute, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Clin Cancer Res 17:2977-86. 2011..Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL... - Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapyGeorge P Canellos
Medical Oncology Hematology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 28:1611-5. 2010..This study examines the impact of chemotherapy alone in treatment of limited-stage, nonbulky HL, radiation therapy eliminated from primary treatment... - Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysisAlfred Ian Lee
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
Cancer 116:3835-42. 2010..The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy. To the best of the authors' knowledge, no consensus exists for postremission surveillance imaging... - Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes databaseMichelle E Kho
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 113:3209-12. 2008..Clinical trials and outcomes studies often rely on nonphysicians to abstract complex data from medical records, but the reliability of these data are rarely assessed... - Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes
Massachusetts General Hospital Cancer Center, Boston, MA, USA
Haematologica 98:615-9. 2013..In conclusion, everolimus in combination with rituximab is well tolerated and demonstrates activity in relapsed diffuse large B-cell lymphoma. Further studies of this combination are warranted... 
Post-transplant lymphoproliferative disordersAnn S LaCasce
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Oncologist 11:674-80. 2006..Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease...- Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disordersJennifer R Brown
Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Haematol 143:361-8. 2008..026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden... - Primary mediastinal large B-cell lymphomaJason E Faris
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA
Clin Adv Hematol Oncol 7:125-33. 2009.... - Biology of double-hit B-cell lymphomasR Coleman Lindsley
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Curr Opin Hematol 19:299-304. 2012..This review summarizes the recent literature regarding the clinical and pathologic features of double-hit lymphomas and outlines current questions about the most accurate and inclusive definition of the disease... - Nodular lymphocyte predominant Hodgkin lymphomaAlfred Ian Lee
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Oncologist 14:739-51. 2009..For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab... - EnzastaurinYi Bin Chen
Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Investig Drugs 17:939-44. 2008..Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC)... - Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 14:418-25. 2008..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population... - Lymphoma: risk and response after solid organ transplantCaron A Jacobson
Division of Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Oncology (Williston Park) 24:936-44. 2010..Further clinical investigation, including randomized controlled trials, will be important in reaching this goal... - Non-Hodgkin's lymphomasAndrew D Zelenetz
J Natl Compr Canc Netw 6:356-421. 2008 - Non-Hodgkin's lymphoma. Clinical practice guidelines in oncologyAndrew D Zelenetz
J Natl Compr Canc Netw 4:258-310. 2006